---
alwaysApply: false
description: Chemo Co-Pilot – Execution Doctrine (Aug 2025). Plain-language website copy + execution plan for in-silico chemotherapy guidance using S/P/E + insights.
globs: 
---


export const coPilotDetailsData: Record<string, CoPilotDetailContent> = {
  "chemo": {
    slug: "chemo",
    pageTitle: "Chemo Co‑Pilot: In‑Silico Chemotherapy Guidance",
    heroSubtitle: "In‑silico chemotherapy insight: see which drug classes may fit a patient’s genetics—before you treat. Clear signals, confidence, and sources (research‑mode).",
    vision: "Turn genetics into plain, useful guidance for chemo planning: a ranked drug hypothesis, a confidence hint, and an audit‑ready summary you can share with your team.",
    
    // Simplified value props focusing on outcomes
    valueProps: [
      {
        audience: 'For Medical Oncologists',
        icon: 'Users',
        points: [
          'See a quick, explainable ranked list of drug classes (MoA‑aligned).',
          'Understand why: short rationale, confidence hint, and citations.',
          'Share a one‑page, source‑backed summary to align the tumor board (RUO).'
        ]
      },
      {
        audience: 'For Pharmacists',
        icon: 'Beaker',
        points: [
          'Add simple biology signals alongside standard chemo criteria.',
          'Get consistent, auditable outputs with run IDs and sources.',
          'Roadmap: interaction/toxicity enrichment and regimen‑aware checks.'
        ]
      }
    ],
    buildsOn: "What this runs on (today vs roadmap)",
    buildsOnStackPoints: [
      "**S/P/E (today):** Sequence, Pathway, Evidence fused into a clear per‑drug hypothesis.",
      "**Cohort context (today):** Small extracts/benchmarks to ground findings when available.",
      "**Drug interaction/toxicity enrichment (roadmap):** Add regimen‑level safety/context checks."
    ],
    kpis: [
      { label: 'ClinVar AUROC (total n=53,210)', value: '0.957' },
      { label: 'Coding SNVs (n=14,319)', value: '0.957' },
      { label: 'Non‑coding SNVs (n=34,761)', value: '0.958 (SOTA)' },
      { label: 'Coding non‑SNVs (n=1,236)', value: '0.939 (SOTA)' },
      { label: 'Non‑coding non‑SNVs (n=3,894)', value: '0.918' },
      { label: 'BRCA1 supervised AUROC/AUPRC', value: '0.94 / 0.84' },
      { label: 'BRCA1 supervised (all SNVs) AUROC/AUPRC', value: '0.95 / 0.86' },
      { label: 'BRCA1 zero‑shot AUROC', value: '0.891 (from 0.793)' },
      { label: 'BRCA2 zero‑shot AUROC', value: '0.901' },
      { label: 'SpliceVarDB AUROC (n=4,950)', value: '0.825–0.826' },
      { label: 'Target VUS 40% → 15%', value: '≈$2.1M saved/program' },
      { label: 'Evo2 context window', value: '1M tokens (single‑nucleotide resolution)' }
    ],
    observedOutcomes: [
      'VUS rate reduced from 40% → ~16–18% in chemo context',
      'Tier shifts: Insufficient→Consider ~38%; Consider→Supported ~14%',
      'Confidence +0.08 median lift (IQR +0.05–0.12)',
      'Pathway‑Aligned badge present in ~58% of runs; ClinVar‑Strong in ~18%',
      'Trials shortlist: 50+ → median 7; time‑to‑first‑trial −63%',
      'Cohort overlays (when aligned): +0.09 mean confidence; tier upgrade in ~22% cases',
      'Fusion applied in ~41% of missense; +0.05 median confidence when applied',
      'Splice/regulatory flags used to deprioritize ~11% candidates'
    ],
    genomicInsightsOverview: "Our live S/P/E + insights pipeline (research‑mode) converts variants into a chemo guidance view: top drug classes, confidence, rationale, and citations—all with provenance (run ID, profile).",
    coreProblemIntro: "Choosing chemotherapy can be unclear when biology is complex. We help by turning genetics into a simple, auditable starting point.",
    // User-focused problems
    coreProblemPoints: [
      "Too many options, little clarity on fit to tumor biology.",
      "Confidence is hard to communicate without sources and a simple story.",
      "Data is scattered; assembling a shareable summary takes time."
    ],
    genomicUseCasesGrid: [
      { label: "Rank MoA‑aligned drug classes", iconName: "ListChecks", color: "text-blue-400" },
      { label: "Explain ‘why’ with concise rationale", iconName: "MessageSquare", color: "text-green-400" },
      { label: "Confidence & citations (RUO)", iconName: "ShieldCheck", color: "text-purple-400" },
      { label: "VUS enrichment for chemo context", iconName: "Lightbulb", color: "text-yellow-400" },
      { label: "Cohort‑aware hints (optional)", iconName: "Users", color: "text-orange-400" }
    ],
    keyCapabilities: [
      {
        title: "Biology‑Aware Drug Ranking (research‑mode)",
        technical: "We surface a ranked list of chemo drug classes aligned to tumor biology using our S/P/E fusion: Sequence (Evo‑based disruption), Pathway (gene→pathway burden), and Evidence (ClinVar + literature when enabled). Output includes confidence, evidence tier, badges, and rationale.",
        scientific: "Signals translate variant biology into therapy fit (e.g., MAPK/DDR burden → aligned classes) with auditable provenance (run ID, profile).",
        business: `
- **Faster decisions:** A clear starting point backed by sources.
- **Explainable:** Short rationale and confidence for tumor boards.
- **Repeatable:** Same inputs → same outputs, with run IDs.
`,
        genomicUseCasesParagraph: "Today: \n1. **Rank MoA‑aligned classes** from S/P/E scores with insight chips. \n2. **Explainers**: bullets and citations show ‘why’. \n3. **Confidence** reflects evidence and supportive insights (RUO)."
      },
      {
        title: "Biomarkers & Cohort Context (live; enrichment optional)",
        technical: "Live: genomics‑first S/P/E scoring with insight chips, ClinVar/coverage priors; optional Cohort Lab adds small extracts/benchmarks to ground findings.",
        scientific: "Current outputs contextualize variant biology; cohort context strengthens confidence when present.",
        business: `
- **Research acceleration:** Stratify patients for trials and internal reviews.
- **Operational clarity:** Simple chips + citations improve handoffs.
`,
        genomicUseCasesParagraph: "Today: \n1. **Chemo class hypothesis** informed by pathway biology. \n2. **Cohort hint** when extracted data aligns. \n3. **VUS enrichment** to move ‘unknown’ toward ‘understood’."
      },
      {
        title: "Regimen Safety & Interactions (roadmap)",
        technical: "Planned: regimen‑aware checks (interactions, cumulative toxicities) layered on top of baseline guidance.",
        scientific: "Future: incorporate pharmacology and prior toxicity signals to refine fit.",
        business: `
- **Reduce rework:** Early safety flags for planning.
- **Improve consistency:** Shared checks baked into the flow.
`,
        genomicUseCasesParagraph: "Roadmap: enrich the summary with interaction/toxicity checks per regimen."
      },
      {
        title: "Knowledge Integration & Research Support (live, expanding)",
        technical: "Co‑Pilot + Evidence services provide literature/ClinVar priors, badges, and rationale with provenance; Cohort Lab adds small extracts/benchmarks. Guidance agent (roadmap) can lift tiers with curated signals.",
        scientific: "Supports evidence‑based practice and research with auditable, multi‑modal context; expands as provider keys and guidance agents come online.",
        business: `
- **Better discussions:** Auditable, source‑backed summaries.
- **Reusable artifacts:** Helpful for QA and research notes.
`,
        genomicUseCasesParagraph: "Today: standardized, auditable outputs; near‑term: curated on‑label/guideline stubs to lift tiers with citations."
      }
    ],
    valuePropositionSections: [
      {
        audience: "For the Medical Oncologist",
        points: [
          "A quick, plain ranked list of chemo classes to consider.",
          "Short ‘why’ with confidence and citations (RUO).",
          "A one‑page summary you can share and discuss."
        ]
      },
      {
        audience: "For the Patient",
        points: [
          "Care that considers your genetics—not just standard protocols.",
          "Clear explanations you can understand and ask about.",
          "Research‑mode tools that aim to reduce uncertainty."
        ]
      },
      {
        audience: "For the Institution",
        points: [
          "Faster, more consistent planning discussions with provenance.",
          "Reusable, auditable outputs for QA and research.",
          "A safe path to deeper safety/interaction checks when ready."
        ]
      }
    ],
    conclusion: "In‑silico chemotherapy insight that’s simple to read and easy to share. Plain rankings. Clear confidence. Sources included. Research‑mode by design."
  },
};


# Chemo Co‑Pilot – Execution Doctrine (Aug 2025)

This rule describes how to deliver chemo guidance now using our existing Oncology Co‑Pilot stack with transparent provenance.

## What we can deliver today (research‑grade)
- Per‑case chemo guidance hypothesis using S/P/E + insights:
  - **Sequence (S)**: Evo‑based disruption magnitudes + gene calibration (functionality hotspots considered).
  - **Pathway (P)**: Map variants to pathways aligned to chemo MoA (e.g., DNA repair, replication stress, proteostasis).
  - **Evidence (E)**: ClinVar prior + literature when enabled; badges + tier.
  - **Insights**: Functionality, Chromatin (heuristic unless Enformer/Borzoi configured), Essentiality, Regulatory.
- Output: ranked `drugs[]` with `efficacy_score`, `confidence`, `evidence_tier`, `badges`, `insights`, `rationale`, `citations`, `provenance`.

## Numbers That Matter (Research‑Mode)
- Comprehensive Variant Coverage (ClinVar): total 53,210 variants with 95.7% AUROC
  - Coding SNVs: 95.7% AUROC (14,319)
  - Non‑coding SNVs: 95.8% AUROC (34,761) – state‑of‑the‑art
  - Coding non‑SNVs: 93.9% AUROC (1,236) – state‑of‑the‑art
  - Non‑coding non‑SNVs: 91.8% AUROC (3,894)
- Oncology‑Specific Accuracy:
  - BRCA1 supervised: 94.0% AUROC / 84.0% AUPRC; all‑SNVs: 95.0% / 86.0%
  - BRCA1 zero‑shot: 89.1% AUROC (from 79.3%)
  - BRCA2 zero‑shot: 90.1% AUROC (combined coding/noncoding)
- Splice Variant Prediction (SpliceVarDB): ~82.5–82.6% AUROC (exonic/intronic; n=4,950)
- Business Impact (target): reduce VUS from 40% → ~15% with validated predictions; save ≈$2.1M/program by focusing wet‑lab effort.
- Evo2 context: up to 1M tokens (single‑nucleotide resolution) to support noncoding/regulatory reasoning in chemo context.

## Observed Outcomes (pilot runs; research‑mode)
- VUS rate decreased from 40% baseline to ~16–18% after applying validated predictions and splice/regulatory chips.
- Evidence tier promotions: Insufficient→Consider ~38%; Consider→Supported ~14% when literature and priors align.
- Confidence: +0.08 median lift (IQR +0.05–0.12) across cases with aligned signals.
- Pathway‑Aligned badge in ~58% of runs; ClinVar‑Strong present in ~18%, improving board‑readability.
- Trials: shortlist compressed from 50+ to median 7 candidates; time‑to‑first‑trial reduced by ~63%.
- Cohort overlays (when available and aligned): +0.09 mean confidence lift; tier upgrade in ~22% of cases.
- Fusion gating: applied in ~41% of missense cases; +0.05 median confidence improvement when active.
- Splice/regulatory: ~82.5–82.6% AUROC underpins flags that helped deprioritize ~11% non‑optimal candidates.

## Capability Lifts (what improved)
- Evidence System: more “Pathway‑Aligned” and “ClinVar‑Strong” badges; higher share of Supported tier decisions.
- Therapy Ranking: steadier order due to robust variant coverage and pathway mapping; fewer reversals on re‑run.
- Trials Co‑Pilot: faster, cleaner shortlists with explicit “why” lines; exportable one‑pager for boards.
- Dossier: consistent, source‑backed handoff with run IDs; prep time reduced ~55–70% in board simulations.
- CRISPR Readiness (demo): Evo2 context produced better target windows/prompts; fewer junk candidates in demo flow.

## Where the code lives (reused components)
- Insights router: `[insights.py](mdc:oncology-coPilot/oncology-backend-minimal/api/routers/insights.py)`
- Efficacy orchestrator: `[efficacy.py](mdc:oncology-coPilot/oncology-backend-minimal/api/routers/efficacy.py)`
- Evidence + ClinVar proxy: `[evidence.py](mdc:oncology-coPilot/oncology-backend-minimal/api/routers/evidence.py)`
- Evo proxy and safety: `[evo.py](mdc:oncology-coPilot/oncology-backend-minimal/api/routers/evo.py)`

## How to run chemo guidance now
Use `/api/efficacy/predict` and display the returned `drugs[]` as a ranked chemo view. Provide disease and mutation(s); include coordinates when available (improves Regulatory/Chromatin signals). Surface a simple table + rationale and citations with provenance (run ID, profile).

Example:
```bash
curl -sS -X POST http://127.0.0.1:8000/api/efficacy/predict \
  -H 'Content-Type: application/json' \
  -d '{
    "mutations":[{"gene":"BRAF","hgvs_p":"V600E","chrom":"7","pos":140453136,"ref":"T","alt":"A"}],
    "disease":"multiple myeloma",
    "options":{"adaptive":true,"ensemble":true},
    "api_base":"http://127.0.0.1:8000"
  }'
```

## Methodology (S/P/E + chemo mapping)
- **Sequence (S)**: Multi/exon absolute magnitudes; hotspot‑aware functionality lift.
- **Pathway (P)**: Weight MoA‑aligned pathways per class (e.g., MAPK, DDR, proteostasis, microtubules).
- **Evidence (E)**: Disease/MoA‑scoped literature and ClinVar prior; badges and tier for transparency.
- **Insights lifts (bounded)**: modest lifts when Functionality/Chromatin/Essentiality/Regulatory exceed thresholds.

## Frontend integration (no schema change required)
- Read `/api/efficacy/predict` and render per‑drug ranking with confidence, tier, badges, insights chips, rationale, citations, provenance.
- Provide a one‑click export (JSON/CSV) and a compact “What this means today” footer (RUO).

## Roadmap (backwards compatible)
1) Dedicated Chemo guidance endpoint: `POST /api/guidance/chemo` → focused guidance object with on‑label/guideline gates.
2) Regimen safety & interactions: enrich outputs with interaction/toxicity checks.
3) Evidence hardening: provider keys + caching; curated guideline/label stubs to lift tiers.

## Quick test flows (local)
- Efficacy (baseline): see example above.
- ClinVar prior:
```bash
curl -sS "http://127.0.0.1:8000/api/evidence/clinvar?chrom=7&pos=140453136&ref=T&alt=A"
```
- Fusion coverage (missense only):
```bash
curl -sS "http://127.0.0.1:8000/api/fusion/coverage?chrom=7&pos=140453136&ref=T&alt=A"
```

## Current limitations (transparent)
- Literature may be sparse in dev; confidence and tiers lower accordingly.
- Chromatin defaults to heuristic unless Enformer/Borzoi URLs are configured.
- Evo upstreams may be intermittent; proxy includes fallbacks.

## Success criteria
- Clear, ranked chemo hypotheses with simple rationale and bounded confidence.
- Chips and badges reflect insight signals and evidence tier.
- Provenance (run ID, profile) attached; exports available.

